|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.49 USD | -2.79% |
|
+0.56% | +37.55% |
| Apr. 11 | Summit Therapeutics Inc. Appoints Dr. Mostafa Ronaghi to Its Board of Directors | CI |
| Apr. 09 | Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed | RE |
Dec 6 (Reuters) - Summit Therapeutics Inc said on Tuesday it has signed a licensing deal worth up to $5 billion with China-based Akeso Inc for an experimental cancer therapy.
Summit said it would make an upfront payment of $500 million, and Akeso will be eligible for regulatory and commercial milestone payments of up to $4.5 billion. (Reporting by Leroy Leo in Bengaluru; Editing by Vinay Dwivedi)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 48.45 HKD | +2.11% | +6.72% | 5.25B | ||
| 3.49 USD | -2.79% | +0.56% | 2.52B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +37.55% | 2.52B | |
| -1.51% | 104B | |
| +3.22% | 97.42B | |
| +0.12% | 22.2B | |
| -16.53% | 21.23B | |
| -10.44% | 18.33B | |
| -42.33% | 16.35B | |
| -20.09% | 15.06B | |
| +5.47% | 13.98B | |
| +28.85% | 11.66B |
SUMMIT THERAPEUTICS INC. 
